Mometasone controlled-release implant - Intersect ENT

Drug Profile

Mometasone controlled-release implant - Intersect ENT

Alternative Names: Bioabsorbable mometasone-eluting sinus implants - Intersect ENT; Mometasone furoate - Intersect; Mometasone furoate implant; Mometasone-eluting stent; Mometasone-releasing S8 sinus implant - Intersect ENT; NOVA sinus implant; PROPEL; PROPEL ContourTM; PROPEL mini; RESOLVE®; SINUVA; Steroid-releasing sinus implant

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intersect ENT
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienediols; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Sinusitis

Most Recent Events

  • 02 Apr 2018 Launched for Sinusitis (New delivery system, Recurrent) in USA (Intranasal)
  • 22 Jan 2018 SINUVA™ will be commercially available for Sinusitis in the US in the second quarter of 2018
  • 22 Jan 2018 Updated safety and efficacy data from the phase III RESOLVE II trials in Sinusitis released by Intersect ENT
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top